Here is a look at Alzheimer’s disease, a progressive brain disorder that leads to loss of memory and other intellectual abilities. Facts Alzheimer’s disease is the most common form of dementia, which ...
Nuvation has a best-in-class lung cancer drug that could be approved in the US in June. Read why I'm bullish on the stock ...
Zacks Investment Research on MSN1d
LLY Rises More Than 4% in a Week: How to Play the StockEli Lilly and Company’s LLY shares have risen 4.3% since it reported fourth-quarter results on Feb. 6. Lilly’s fourth-quarter ...
U.S. investors and large pharmaceutical companies are increasingly doing deals in China as the country’s biopharma sector ...
Eli Lilly continues to see strong growth coming from its GLP-1 drugs. The company's current 2025 guidance looks conservative.
For years, people taking Ozempic or other drugs in the same class for diabetes and weight loss have noticed the medicines don ...
The results add to evidence from animal studies and reports that people are finding the drugs helpful to manage cravings, not ...
Novartis, Eli Lilly and more put on their deal-making caps, Bristol Myers Squibb targets $2 billion in savings through 2027, ...
Pharmaceutical Technology on MSN3d
Eli Lilly pledges $630m on OliX’s Phase I RNA candidate for MASHLilly will provide an initial payment to complete a Phase I trial of OLX75016, which started in February 2024.
Immunotherapy, which uses programmed immune cells to selectively destroy cancer cells, has transformed cancer treatment.
Compounding pharmacies aren’t the only makers of off-brand versions of Novo Nordisk’s Wegovy and Eli Lilly’s Zepbound. The ...
Eli Lilly strengthens its pipeline with AdvanCell for targeted alpha therapies and partners with OliX to advance OLX75016 for ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback